Core Viewpoint - Ipsen announced a positive opinion from the CHMP recommending conditional marketing authorization for Ojemda® (tovorafenib) to treat pediatric low-grade glioma (pLGG) in patients aged 6 months and older with specific BRAF alterations who have progressed after prior therapies [1][7]. Group 1: Treatment Landscape - Over 800 new cases of BRAF altered pLGG are identified annually in the EU, leading to significant disabilities and a complex treatment journey involving surgeries and multiple therapies [2][16]. - Current treatment options for relapsed/refractory pLGG have been limited for decades, highlighting the need for targeted therapies like tovorafenib [4]. Group 2: Clinical Data and Efficacy - The positive CHMP opinion is based on the Phase II FIREFLY-1 study, which involved 137 children and young adults with relapsed or refractory BRAF-altered pLGG [4][14]. - The study showed an overall response rate of 71% per RANO-HGG criteria and 53% per RAPNO-LGG criteria, with a clinical benefit rate of 77% and 58% respectively [6]. - Among responders, the median time to response was 5.4 months, and the median duration of response was 18.0 months [6]. Group 3: Safety and Administration - Tovorafenib demonstrated a manageable safety profile, with a low discontinuation rate of 9.5% due to treatment-related adverse events, which were primarily Grade 1 or 2 [6]. - The drug offers convenient once-weekly oral dosing, available in both liquid and tablet forms, minimizing disruption to patients' daily routines [6]. Group 4: Regulatory Status and Future Prospects - Following the positive opinion from the CHMP, the European Commission will review the recommendation, with a final decision on marketing authorization expected soon [7]. - Tovorafenib is already approved in the U.S. for similar indications and has received Breakthrough Therapy and Rare Pediatric Disease designations from the FDA [11][9].